

Addenbrooke's Hospital
Research & Development Department
Box 277
Cambridge Biomedical Campus
Hills Road, Cambridge, CB2 0QQ

E research@addenbrookes.nhs.uk
W www.cuh.nhs.uk

Results Report

EudraCT No: 2016-004974-16
Full Title: Double-blind placebo-controlled randomised clinical dose-range study treating severe traumatic brain injury patients with recombinant Interleukin 1 receptor antagonist.
End Date: 8th September 2020

Results:

Due to logistical issues and changes in routine practice during the trials development and set-up, this trial terminated prior to opening for recruitment. Zero (0) patients were recruited to the trial and therefore no results are available.



Carrie Bayliss
Regulatory & Quality Manager